Correction: Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer - Cell Death & Disease
Nature
Last updated: April 24, 2026
This article, available under a Creative Commons Attribution 4.0 International License, permits broad reuse of its content. The license allows for use, sharing, adaptation, distribution, and reproduction across various media and formats, provided appropriate credit is given to the original author(s) and source. This signifies an open access publication model, aiming to promote wider dissemination and accessibility of research or information.
- The core of the article, as indicated by its licensing, revolves around the principles of open access. This model is designed to make content freely available to the public, removing financial and legal barriers to access. Such an approach encourages collaboration, innovation, and the rapid advancement of knowledge by enabling anyone to read, download, copy, distribute, print, search, or link to the full texts of scientific articles. The license specifically requires attribution, meaning users must acknowledge the original source when utilizing the material. This ensures that authors receive credit for their work while still facilitating its broad application. The flexibility of the license extends to adaptation and remixing, allowing for the creation of derivative works, further promoting the creative reuse and evolution of the original content.
